Atara Biotherapeutics, Inc.
ATRA
$10.51
$0.292.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -88.41% | -6.33% | 51.27% | 202.41% | 475.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.41% | -6.33% | 51.27% | 202.41% | 475.53% |
| Cost of Revenue | -92.69% | -67.64% | -60.35% | -36.28% | -28.16% |
| Gross Profit | -75.27% | 367.76% | 200.60% | 154.50% | 128.00% |
| SG&A Expenses | -56.49% | -39.55% | -25.63% | -13.31% | -15.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -84.85% | -63.14% | -47.99% | -26.28% | -20.57% |
| Operating Income | -136.43% | 156.65% | 131.48% | 111.58% | 98.54% |
| Income Before Tax | 39.81% | 138.31% | 117.58% | 103.18% | 93.27% |
| Income Tax Expenses | 186.11% | 358.33% | -33.33% | -306.25% | -311.76% |
| Earnings from Continuing Operations | 39.47% | 138.28% | 117.57% | 103.20% | 93.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.47% | 138.28% | 117.57% | 103.20% | 93.29% |
| EBIT | -136.43% | 156.65% | 131.48% | 111.58% | 98.54% |
| EBITDA | -336.42% | 166.14% | 136.53% | 115.30% | 101.04% |
| EPS Basic | 81.95% | 124.56% | 108.67% | 99.00% | 93.03% |
| Normalized Basic EPS | 72.60% | 133.36% | 114.06% | 101.75% | 94.61% |
| EPS Diluted | 81.88% | 124.24% | 108.51% | 98.90% | 92.97% |
| Normalized Diluted EPS | 72.85% | 133.04% | 113.90% | 101.64% | 94.54% |
| Average Basic Shares Outstanding | 52.39% | 67.48% | 100.51% | 102.17% | 90.58% |
| Average Diluted Shares Outstanding | 52.33% | 68.15% | 101.36% | 103.16% | 91.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |